High-profile departure ends genome institute's charmed run

  title={High-profile departure ends genome institute's charmed run},
  author={Meredith Wadman},
  journal={Nature Medicine},
  • M. Wadman
  • Published 26 April 2007
  • Medicine
  • Nature Medicine
It is too early to tell. If the current adenovirus-based trials show some degree of protection or control of viral load, then we have a substantial beachhead from which to work. Barton Haynes director Center for HIV-AIDS Vaccine Immunology I think we will have something that modulates infection soon. [But] will we have something in a vial that’s being distributed in the developing world? Highly unlikely. Bruce Walker professor of medicine Harvard University urvey says... N E W S 
2 Citations
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.
It is shown for the first time that intravaginal administration with nanoparticles of poly(lactic-co-glycolic acid) (PLGA) encapsulating short interfering RNA (siRNA) molecules is effective for prevention of genital HSV-2 infections in mice. Expand
Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs
The intravaginal delivery of proteins and oligonucleotides is addressed, with specific application to HSV and HIV, and the integration of more targeted delivery modalities to virus and host cells is proposed. Expand